NICE recommends first-in-class asthma treatment
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment mepolizumab, in draft guidance for adults with severe asthma, reversing a negative earlier decision.
UK pharma major GlaxoSmithKline’s (LSE: GSK) Nucala (mepolizumab) is the first biologic treatment to target specific white blood cells called eosinophils, which are responsible for symptoms in thousands of asthma patients, says the cost-effectiveness watchdog for England and Wales, adding thatpeople with the most severe symptoms, including those who suffer multiple asthma attacks, will soon have access to mepolizumab as an extra treatment option.
NICE’s decision follows marketing authorisation in Europe in December 2015 and positive restricted advice by the Scottish Medicines Consortium for use within NHS Scotland in June 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze